Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAX-1 monotherapy for recurrent glioblastoma
ACTRN12619000640101Phase 2Completed
- Sponsor
- Novotech
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sodium arsenite in glioblastoma (GBM), sponsored by Novotech. Primary endpoint: Median progression-free survival. Started Feb 2020; status: completed.
02
Drugs
sodium arsenite
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12619000640101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000640101.